United
      States


**SECURITIES
      AND EXCHANGE COMMISSION**


WASHINGTON,
      D.C. 20549





**FORM
      10-QSB/A**


**(AMENDMENT
      NO.1)**





[
                X
                ]
            QUARTERLY
                REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
                ACT OF
                1934





For
      the
      quarterly period ended **March
      31, 2006**





[
                ]
            TRANSITION
                REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
                ACT OF
                1934





Commission
      File Number 0-20791





**AMARILLO
      BIOSCIENCES, INC.**


(Exact
      name of small business issuer as specified in its charter)





TEXAS
            75-1974352(State
                or other jurisdiction of
            (IRS
                Employer Identification No.)incorporation
                or organization)





4134
                Business Park Drive, Amarillo, Texas
            79110(Address
                of principal executive offices)
            (Zip
                Code)





806-376-1741
            FAX
                806-376-9301(Issuer's
                telephone number, including area code)





Check
      whether the issuer (1) filed all reports required to be filed by Section 13
      or
      15(d) of the Exchange Act during the past 12 months (or for such shorter period
      that the registrant was required to file such reports), and (2) has been subject
      to such filing requirements for the past 90 days. Yes X .
      No  .





Indicate
      by check mark whether the registrant is a shell company (as defined in Rule
      12b-2 of the Exchange Act) Yes  No X .





As
      of
      March 31, 2006 there were 21,282,203 shares of the issuer's common stock
      outstanding.





Transitional
      Small Business Disclosure Format (check one) Yes ___. No X .


1


**Explanatory
      Note**







This
      Quarterly Report on Form 10-QSB/A is being filed as Amendment Number 1 to our
      Quarterly Report on Form 10-QSB which was originally filed with the Securities
      and Exchange Commission (‘‘SEC’’) on May 11, 2006. This Form 10-QSB/A has been
      amended to provide currently-dated certifications in the form required by Item
      601(b)(31) of Regulation S-B. These certifications are attached to this
      Form 10-QSB/A as Exhibits 31.1a and 31.1b.





For
      the
      convenience of the reader, this Form 10-QSB/A sets forth the entire Form 10-QSB
      which was prepared and relates to the Company as of March 31, 2006. However,
      this Form 10-QSB/A only amends and restates the Item described above and no
      attempt has been made to modify or update other disclosures presented in our
      March 31, 2006 Form 10-QSB. Accordingly, except for the foregoing amended
      information, this Form 10-QSB/A continues to speak as of May 11, 2006 (the
      original filing date of the March 31, 2006 Form 10-QSB), and does not reflect
      events occurring after the filing of our March 31, 2006 Form 10-QSB and does
      not
      modify or update those disclosures affected by subsequent events. Forward
      looking statements made in the March 31, 2006 Form 10-QSB have not been revised
      to reflect events, results or developments that have become known to us after
      the date of the original filing (other than the current restatement described
      above), and such forward looking statements should be read in their historical
      context. Unless otherwise stated, the information in this Form 10-QSB/A not
      affected by such current restatements is unchanged and reflects the disclosures
      made at the time of the original filing.






2




**AMARILLO
      BIOSCIENCES, INC.**




INDEX








PAGE
                NO.PART
                I:
            FINANCIAL
                INFORMATIONITEM
                1.
            Financial
                StatementsConsolidated
                Balance Sheet - March 31, 2006
            4Consolidated
                Statements of Operations - Three Months Ended March 31, 2006 and
                March 31,
                2005
            5Condensed
                Consolidated Statements of Cash Flows - Three Months Ended March
                31, 2006
                and 2005
            6Notes
                to Consolidated Financial Statements
            7ITEM
                2.
            Management's
                Discussion and Analysis of Financial Condition and Results of
                Operations
            9ITEM
                3.
            Controls
                and Procedures
            12PART
                II:
            OTHER
                INFORMATIONITEM
                2.
            Unregistered
                Sales of Equity Securities and Use of Proceeds
            12ITEM
                6.
            Exhibits
            13Signatures
            
            14





3


**PART
      I - FINANCIAL INFORMATION**





**Item
      1.**  **Financial
      Statements**





Amarillo
      Biosciences, Inc. and Subsidiaries


Consolidated
      Balance Sheet - Unaudited


March
      31,
      2006





**Assets**Current
                  assets:Cash
              
              $
                  379,233Other
                  current assets
              
              1,799Total
                  current assets
              
              381,032Equipment,
                  net
              
              2,118Patents,
                  net of accumulated amortization of $194,884
              
              115,812Total
                  assets
              
              $
                  498,962**Liabilities
                  and Stockholders' Deficit**Current
                  liabilities:Accounts
                  payable
              
              $
                  40,233Accrued
                  interest expense
              
              532,832Notes
                  payable
              
              2,025,000Total
                  current liabilities
              
              2,598,065Total
                  liabilities
              
              2,598,065Commitments
                  and contingenciesStockholders'
                  deficitPreferred
                  stock, $.01 par value:Authorized
                  shares - 10,000,000Issued
                  shares - none
              
              -Common
                  stock, $.01par value:Authorized
                  shares - 50,000,000Issued
                  shares - 21,282,203
              
              
              212,822Additional
                  paid-in capital
              
              
              21,635,300Accumulated
                  deficit
              
              
              (23,947,225
              )Total
                  stockholders' deficit
              
              
              (2,099,103
              )Total
                  liabilities and stockholder's deficit
              
              $
              498,962


*See
      accompanying notes to financial statements.*


4


Amarillo
      Biosciences, Inc. and Subsidiaries


Consolidated
      Statements of Operations - Unaudited





Three
                  months ended March 31,2006
              
              
              2005Revenues:Dietary
                  supplement sales
              
              $
              853
              
              $
              876License
                  fee
              
              
              30,000
              
              
              -Total
                  Revenues
              
              
              30,853
              
              
              876Expenses:Cost
                  of sales
              
              
              -
              
              
              8Research
                  and development expenses
              
              
              96,238
              
              
              42,527Selling,
                  general and administrative expenses
              
              
              681,442
              
              
              132,348Interest
                  expense
              
              
              24,181
              
              
              23,791Total
                  Expenses
              
              
              801,861
              
              
              198,674Net
                  income (loss)
              
              $
              (771,008
              )
              $
              (197,798
              )Basic
                  and diluted net income (loss) per share
              
              
              (0.04
              )
              
              (0.01
              )Weighted
                  average shares outstanding
              
              
              20,360,871
              
              
              16,086,523


*See
      accompanying notes to financial statements*


5


Amarillo
      Biosciences, Inc. and Subsidiaries


Condensed
      Consolidated Statements of Cash Flows - Unaudited





Three
                  months ended March 31,2006
              
              
              2005Net
                  cash used in operating activities
              
              $
              (266,405
              )
              $
              (137,832
              )Cash
                  from investing activities:Purchases
                  of equipment
              
              
              (1,461
              )
              
              -Cash
                  from financing activities:Proceeds
                  from issuance of common stock
              
              
              522,284
              
              
              140,480Repayments
                  on notes payable
              
              
              (68,500
              )
              
              -Net
                  cash provided by (used in) financing activities
              
              
              453,784
              
              
              140,480Net
                  increase (decrease) in cash
              
              
              185,918
              
              
              2,648Cash
                  at beginning of period
              
              
              193,315
              
              
              6,283Cash
                  at end of period
              
              $
              379,233
              
              $
              8,931Supplemental
                  Disclosure of Cash Flow InformationCash
                  paid for interest
              
              $
              2,050
              
              $
              2,431


*See
      accompanying notes to financial statements.*


6


**Amarillo
      Biosciences, Inc. and Subsidiaries**





**Notes
      To Consolidated Financial Statements - Unaudited**





1.
            Basis
                of presentation. The accompanying consolidated financial statements,
                which
                should be read in conjunction with the consolidated financial statements
                and footnotes included in the Company's Form 10-KSB for the year
                ended
                December 31, 2005 filed with the Securities and Exchange Commission,
                are
                unaudited, but have been prepared in accordance with accounting principles
                generally accepted in the United States for interim financial information.
                Accordingly, they do not include all of the information and footnotes
                required by accounting principles generally accepted in the United
                States
                for complete financial statements. In the opinion of management,
                all
                adjustments (consisting only of normal recurring adjustments) considered
                necessary for a fair presentation have been
                included.





Operating
      results for the three months ended March 31, 2006 are not necessarily indicative
      of the results that may be expected for the full year ending December 31,
      2006.





2.
            Stock
                based compensation. Effective January 1,
                2006, the Company adopted SFAS No.
                123 (revised), "Share-Based Payment" (SFAS 123(R)) utilizing the
                modified prospective approach. Prior to the  adoption of SFAS 123(R)
                we  accounted  for stock  option  grant in
                accordance  with APB Opinion No. 25,  "Accounting for Stock
                Issued to Employees," and accordingly, recognized compensation
                expense for stock option grants using the intrinsic value
                method.





Under
      the
      modified prospective approach, SFAS 123(R) applies to new awards and
      to awards that were outstanding on January 1, 2006 that
      are subsequently modified, repurchased or cancelled.  Under the
      modified prospective approach, compensation cost recognized in
      the first quarter of fiscal 2006 includes compensation cost for
      all share-based payments granted prior to, but not yet vested as of January
      1,
      2006, based on the grant-date fair value estimated in accordance with the
      original  provisions of SFAS 123, and compensation cost for all
      share-based payments granted subsequent  to January 1, 2006 based
      on the grant-date fair value estimated in accordance with the
      provisions of SFAS 123(R).  Prior periods were not restated to reflect
      the impact of adopting the new standard.





The
      following table illustrates the effect on net loss and net loss per share if
      Amarillo had applied the fair value provisions of FASB Statement No. 123,
      Accounting for Stock-Based Compensation, to stock-based employee compensation
      prior to January 1, 2006.


7


Three Months
                  ended
                March
                  31, 2005Net
                  loss, as reported
              
              $
              (197,799
              )Less:
                  stock based compensation determined
                under
                  fair value based method
              
              
              (181,105
              )Pro
                  forma net loss
              
              $
              (378,904
              )Basic
                  and diluted net loss per shareAs
                  reported
              
              $
              (0.01
              )Pro
                  forma
              
              $
              (0.02
              )





The
      fair
      value of each option granted is estimated on the date of grant using the
      Black-Scholes option-pricing model with the following weighted average
      assumptions: dividend yield 0.0%, expected volatility of 138.31%, risk-free
      interest rate of 1.5% and expected life of 60 months.





3.
            Loss
                per share. Loss per share is computed based on the weighted average
                number
                of common shares outstanding.





4.
            Financial
                Condition. The Company's viability is dependent upon successful
                commercialization of products resulting from its research and product
                development activities. The Company plans on working with commercial
                development partners in the United States and in other parts of the
                world
                to provide the necessary sales, marketing and distribution infrastructure
                to successfully commercialize the interferon alpha product for both
                human
                and animal applications. The Company's products will require significant
                additional development, laboratory and clinical testing and investment
                prior to the Company obtaining regulatory approval to commercially
                market
                its product(s). Accordingly, for at least the next few years, the
                Company
                will continue to incur research and development and general and
                administrative expenses and may not generate sufficient revenues
                from
                product sales to support its
                operations.





5.
            Line
                of Credit. The Company has aline
                of credit with Wells Fargo for $10,000, with interest at the prime
                rate
                plus 6.75 percent. There was no outstanding balance at March 31,
                2006.





6.
            Equity.
                During the quarter ended March 31, 2006, the Board of Directors authorized
                the issuance of 9,033 shares of restricted common stock to consultants
                in
                lieu of cash payments. Based upon the common stock trading price
                at the
                time of issuance, a non-cash consulting expense of $5,200 was recorded
                for
                the issuance of these shares during the first quarter of 2006. The
                Board
                of Directors also authorized the issuance of 274,000 options to purchase
                restricted common stock at a discounted price to consultants for
                service,
                in lieu of cash payments. These options have not been exercised,
                but have
                been recognized as follows: 24,000 options, vesting 2,000 options
                per
                month, were valued at $8,951, for the first quarter and 250,000 options,
                vesting immediately valued at


8


$224,448.
      The accumulated value of the above mentioned stock and stock options for the
      first quarter is $238,599 for non-cash consulting compensation.





During
      the three months ended March 31, 2006, the Company recognized $216,000 (fair
      value) of expense in connection with the February 2006 grant of 300,000 shares
      of stock to an employee of the Company.  The certificate is expected to be
      issued in the second quarter of 2006.





In
      the
      first three months of 2006, the Company completed private equity financing
      by
      selling 1,471,300 restricted shares of common stock at a discount to 8
      investors. The net proceeds to the Company were approximately
      $522,000.




7.
            License
                Fee. License fee revenue is recognized upon completion of all significant
                initial services provided to the licensee and upon satisfaction of
                all
                material conditions of the license agreement.  In the first quarter
                of 2006 ABI entered into a License and Supply Agreement whereby the
                Company received and earned $30,000 as an initial license
                fee.





**Item
                2.**
            **Management's
                Discussion and Analysis of Financial Condition and Results of
                Operations**





*The
      following discussion should be read in conjunction with our financial statements
      and the notes thereto which appear elsewhere in this report. The results shown
      herein are not necessarily indicative of the results to be expected in any
      future periods. This discussion contains forward-looking statements based on
      current expectations, which involve uncertainties. Actual results and the timing
      of events could differ materially from the forward-looking statements as a
      result of a number of factors. Readers should also carefully review factors
      set
      forth in other reports or documents that we file from time to time with the
      Securities and Exchange Commission.*





In
      the
      first quarter, the Company completed private equity financing by selling
      restricted stock at a discount to 8 investors. The net proceeds to the Company
      were approximately $522,000.




During
      the first quarter of 2006, ABI worked in three areas to improve the Company.
      These are the areas 1) agroterrorism, 2) partner discussions, and 3)
      sales.




*Agroterrorism* .
      Teel
      Bivins was retained as a consultant in April 2006 to help advance our position.




*Nutraceutical
      Product* .
      ABI
      sells ACM as Maxisal® to individuals and to pharmacies in the USA and to
      licensed distributors overseas.




*Partner/License
      Discussions.* The
      Company is presently negotiating with human health commercial development
      partners in various regions of the world including South America, the United
      States and South East Asia. These agreements could generally include provisions
      for the commercial partner to pay the Company a technology access fee, could
      include payments for a portion of the clinical trial expenses, could include
      payment obligations to the Company upon the accomplishment of certain defined
      tasks and/or could provide for




9


payments
      relating to the future sales of commercial product. These agreements could
      be an
      important source of funds for the Company. However, there can be no assurance
      that the Company will be successful in obtaining additional funding from either
      human health and animal health commercial development partners or private
      investors. If the Company is not successful in raising additional funds, it
      will
      need to significantly curtail clinical trial expenditures and to reduce staff
      and administrative expenses and may be forced to cease operations.




The
      Company has launched a myeloproliferative diseases study at a major cancer
      center in Texas. The myeloproliferative diseases to be studied are polycythemia
      vera and essential thrombocythemia. An investigational new drug (IND)
      application was filed with the US Food and Drug Administration (FDA) in the
      second quarter of 2005 and the patients are being enrolled and evaluated
      now.




The
      Turkish government has granted permission to conduct a study there on 90
      patients with Behcet’s disease. Nobel ILAC and the Company have agreed to
      collaborate on a 12-week study of treatment with interferon lozenges in order
      to
      evaluate prevention of recurrence of oral ulceration. The IND application was
      submitted to the FDA and approved by the Turkish Ministry of Health on October
      18, 2005. The first patient was enrolled in April of 2006.




*Subsequent
      Event* .
      Gary W.
      Coy, PhD, MBA joined the Company on April 15, 2006 as Chief Financial Officer.
      Dr. Coy’s business and scientific background brings additional depth to the
      management team.




Results
      of Operations:




Revenues.
      During the three-month period ended March 31, 2006, $853 from product sales
      was
      generated compared to revenues from product sales for the three-month period
      ended March 31, 2005, of $876, a decrease of $23 or approximately 2.6%. There
      have been no sales of interferon products in 2006. ABI entered into a License
      and Supply Agreement whereby the Company received and earned $30,000 as an
      initial license fee.




Selling,
      General and Administrative Expenses. Selling, General and Administrative
      expenses of $681,442 were incurred for the three-month period ended March 31,
      2006, compared to $132,348 for the three-month period ended March 31, 2005,
      an
      increase of $549,094. This included $238,599 in non-cash expenses in recognition
      of restricted stock issued to cover services provided by consultants in lieu
      of
      cash, and options to purchase restricted stock in lieu of cash. Also included
      in
      this amount is $216,000 for a stock bonus awarded on February 20,
      2006.




Non-Cash
      Consulting Activities. During the three-month period ended March 31, 2006,
      the
      Board of Directors authorized the issuance of shares of restricted common stock
      to a consultant in lieu of cash payments. Based upon the common stock trading
      price at the times of issuance, and FASB rules, a non-cash consulting expense
      of
      $5,200 was recorded for the issuance of these shares during the three-month
      period ended March 31, 2006. Additionally, the Board authorized the issuance
      of
      274,000 options to purchase restricted common stock at a discounted price to
      consultants for service, in lieu of cash payments.


10


Net
      Income (Loss). As a result of the above, in the three-month period ended March
      31, 2006, the Company's Net Loss was ($771,008) compared to a Net Loss for
      the
      three-month period ended March 31, 2005 of ($197,798). This increased loss
      is
      primarily due to an increase in funding, research activity and stock option
      recognition.





Liquidity
      Needs:




At
      March
      31, 2006, the Company had available cash of approximately $379,233, and had
      a
      working capital deficit of approximately ($1,192,033). Assuming there is no
      decrease in current accounts payable, and accounting for various one-time
      expenses, the Company’s negative cash flow is approximately $39,000 per month.
      The Company's continued losses and lack of liquidity indicate that the Company
      may not be able to continue as a going concern for a reasonable period of time.
      The Company's ability to continue as a going concern is dependent upon several
      factors including, but not limited to, the Company's ability to generate
      sufficient cash flows to meet its obligations on a timely basis, obtain
      additional financing and continue to obtain supplies and services from its
      vendors. The Company will need to raise additional funds in order to fully
      execute its 2006 Plan.




Forward-Looking
      Statements: Certain statements made in this Plan of Operations and elsewhere
      in
      this report are "forward-looking statements" within the meaning of the Private
      Securi-ties Litigation Reform Act of 1995 (the "Act"). Forward-looking
      statements include, without limitation, any statement that may predict,
      forecast, indicate or imply future results, performance, achievements, costs
      or
      expenses and may contain words such as "believe," "anticipate," "expect,"
      "esti-mate," "project," "budget," or words or phrases of similar meaning.
      Forward-looking statements involve risks and uncertainties which may cause
      actual results to differ materially from those projected in the forward-looking
      statements. Such risks and uncertain-ties are detailed from time to time in
      reports filed by the Company with the Securities and Exchange Commission,
      including Forms 8-K, 10-QSB and 10-KSB and include among others the following:
      promulga-tion and imple-mentation of regulations by the U.S. Food and Drug
      Administra-tion ("FDA"); promul-gation and implementation of regulations by
      foreign governmen-tal instru-mentalities with functions similar to those of
      the
      FDA; costs of research and develop-ment and clinical trials, including without
      limitation, costs of clinical supplies, packaging and inserts, patient
      recruitment, trial monitoring, trial evaluation and publication; and possible
      difficulties in enrolling a sufficient number of qualified patients for certain
      clinical trials. The Company is also dependent upon a broad range of general
      economic and financial risks, such as possible increases in the costs of
      employing and/or retaining qualified personnel and consultants and possible
      inflation which might affect the Company's ability to remain within its budget
      forecasts. The principal uncertain-ties to which the Company is presently
      subject are its inability to ensure that the results of trials performed by
      the
      Company will be sufficiently favorable to ensure eventual regulatory approval
      for commercial sales, its inability to accurately budget at this time the
      possible costs associated with hiring and retaining of additional personnel,
      uncertainties regarding the terms and timing of one or more commercial partner
      agreements and its ability to continue as a going concern.




The
      risks
      cited here are not exhaustive. Other sections of this report may include
      additional factors which could adversely impact the Company's business and
      future prospects. Moreover, the Company is engaged in a very competitive and
      rapidly changing industry.




11


New
      risk
      factors emerge from time to time and it is not possible for management to
      predict all such risk factors, nor can it assess the impact of all such risk
      factors on the Company's business, or the extent to which any factor or
      combination of factors may cause actual results to differ materially from those
      projected in any forward-looking statements. Given these risks and
      uncertainties, investors should not place undue reliance on forward-looking
      statements as a prediction of actual future events.




**Item
                3.**
            **Controls
                and Procedures**




As
      required by Rule 13a-15 under the Exchange Act, we have carried out an
      evaluation of the effectiveness of the design and operation of our company’s
      disclosure controls and procedures as of the end of the period covered by this
      quarterly report, being March 31, 2006. This evaluation was carried out under
      the supervision and with the participation of our company’s management,
      including our company’s president and chief executive officer. Based upon that
      evaluation, our company’s president and chief executive officer concluded that
      our company’s disclosure controls and procedures are effective as at the end of
      the period covered by this report. There have been no significant changes in
      our
      company’s internal controls or in other factors, which could significantly
      affect internal controls subsequent to the date we carried out our
      evaluation.




Disclosure
      controls and procedures are controls and other procedures that are designed
      to
      ensure that information required to be disclosed in our company’s reports filed
      or submitted under the Exchange Act is recorded, processed, summarized and
      reported, within the time periods specified in the Securities and Exchange
      Commission’s rules and forms. Disclosure controls and procedures include,
      without limitation, controls and procedures designed to ensure that information
      required to be disclosed in our company’s reports filed under the Exchange Act
      is accumulated and communicated to management, including our company’s president
      and chief executive officer as appropriate, to allow timely decisions regarding
      required disclosure.






**PART
      II - OTHER INFORMATION**




**Item
      2.**  **Unregistered
      Sales of Equity Securities and Use of Proceeds**




During
      the quarter ended March 31, 2006, the Board of Directors authorized the issuance
      of 9,033 shares of restricted common stock to consultants in lieu of cash
      payments. Based upon the common stock trading price at the time of issuance,
      a
      non-cash consulting expense of $5,200 was recorded for the issuance of these
      shares during the first quarter of 2006. Both issuances were to Biotech
      Financial and were exempt from registration under Rule 504 of Regulation D
      promulgated pursuant to the Securities Act of 1933. Biotech Financial provided
      financial consulting services as consideration for the shares.





The
      first
      issuance occurred on January 10, 2006, in the amount of 4,385 shares, and was
      valued at $1,900.00 at a per share price of $.433, representing a discount
      of
      $.037 per share, as shares of the Company closed at $.47 on that
      date.


12


The
      second issuance occurred on February 8, 2006, in the amount of 4,648 shares,
      and
      was valued at $3,300.00 at a per share price of $.71, representing a discount
      of
      $.02 per share, as shares of the Company closed at $.73 on that date.





In
      the
      quarter ended March 31, 2006, the Company completed private equity financing
      by
      selling 1,471,300 restricted shares of common stock at a discount to 8
      investors. The shares are restricted and are transferable pursuant to Rule
      144
      promulgated under the Securities Act of 1933. The net proceeds to the Company
      were approximately $522,260. All shares sold were exempt from registration
      pursuant to Rule 506 of Regulation D, promulgated pursuant to the Securities
      Act
      of 1933. No underwriters were involved in any of the unregistered share sales
      and no commissions were paid.







**Date
                (2006)**
            **Shares**
            **Purchaser**
            **Discount*****Issue
                Price**
            **Number**
            **Per
                Share**
            **Total**1
            January
                19
            .2
            200000
            Sean
                Brooks
            .32
            640002
            January
                19
            .2
            250000
            Thomas
                Ulie
            .32
            800003
            January
                24
            .2
            50000
            Martin
                Lechner
            .7
            350004
            January
                26
            .2
            21300
            Thomas
                Ulie
            .67
            142715
            February
                16
            .2
            150000
            Nicolas
                Martin
            .51
            765006
            March
                8
            .38
            200000
            Thomas
                Ulie
            .43
            860007
            March
                28
            .52
            100000
            Thomas
                Huebner
            .9
            900008
            March
                28
            .52
            300000
            Calder
                Capital, Inc.
            .9
            2700009
            March
                29
            .52
            100000
            Bernhard
                Tewaag
            1.06
            10600010
            March
                30
            .52
            100000
            Hauck
                & Aufhaeuser
            1.19
            119000


*Discounts
      were calculated based on the last transaction on each date.







**Item
                6.**
            **Exhibits.**




None.




13


**SIGNATURES**




Pursuant
      to the requirements of Securities Exchange Act of 1934, the Registrant has
      duly
      caused this report to be signed on its behalf by the undersigned thereunto
      duly
      authorized.




**AMARILLO
      BIOSCIENCES, INC.**









Date:
                December 28,
                2006
            By:/s/
                Joseph M. CumminsJoseph
                M. CumminsPresident
                and Chief Executive Officer





Date:
                  December 28,
                  2006
              By:/s/
                  Gary CoyGary
                  CoyVice
                  President and Chief Financial
                  Officer


14